ResearchMoz

Afatinib (Breast Cancer) - Analysis and Forecasts to 2020

GlobalData
Published Date » 2011-12-31
No. Of Pages » 45


GlobalDatas pharmaceuticals report, Afatinib (Breast Cancer) - Analysis and Forecasts to 2020 provides Afatinib sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2017-2020). The report also includes information on Breast Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Afatinib including sales data 
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Afatinib including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2017-2020 for Afatinib in the seven major markets

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Keywords

Afatinib, Breast cancer, Sales forecast, Phase III, Phase 3, Tyrosine Kinase Inhibitor (HER2, EGFR inhibitor), Competitors to Neratinib, Afinitor and Taxotere, Boehringer Ingelheim, Targeted therapy, Breast cancer, pipeline
Table of Contents

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 4

2 Introduction 5
2.1 Breast Cancer Market 5
2.2 Epidemiology 5
2.3 Etiology and Risk Factors 7
2.3.1 Age and Gender 7
2.3.2 Genetic Inheritance 7
2.3.3 Hormone Replacement Therapy 7
2.3.4 Radiation 7
2.3.5 Obesity 7
2.3.6 Alcohol Consumption 7
2.3.7 Late Child Birth 7
2.3.8 Use of Birth Control Pills 7
2.4 GlobalData Report Guidance 8

3 Breast Cancer: Market Characterization 9
3.1 Breast Cancer Market 9
3.2 Breast Cancer Market Forecasts and CAGR 9
3.3 Drivers of Breast Cancer Market 10
3.3.1 Breast Cancer: Most Frequent Cancer in Women 10
3.3.2 Increasing Breast Cancer Incidence Rate 10
3.3.3 Decreasing Breast Cancer Mortality Rate 12
3.3.4 High Survival Rates of Breast Cancer 14

4 Staging of Breast Cancer: Introduction 15
4.1 Distribution of Patients by Stages 15
4.1.1 Stages 15

5 Predictive Biomarker in the Treatment of Breast Cancer 17

6 Treatment Options of Breast Cancer 19

6.1 Stage 0 Breast Cancer 19
6.2 Early Stage Breast Cancer (Excluding Stage 0) 20
6.3 Metastatic Breast Cancer (MBC) 22
6.3.1 Endocrine Treatment: Adjuvant, First Line and Second Line 22
6.3.2 Cytotoxic Chemotherapy 24
6.3.3 Management of Patients with HER-2 Positive Patients 26

7 Afatinib 28
7.1 Introduction 28
7.2 Mechanism of Action 28
7.3 Clinical Studies 28
7.3.1 Phase III trial 28
7.3.2 Phase II trial 28
7.4 Factors Affecting Sales of Afatinib 29
7.4.1 Helps increasing Progression Free Survival 29
7.4.2 Less Toxicity 29
7.4.3 Benefit to Herceptin-Refractory Breast Cancer 29
7.5 Drug Evaluation 30
7.5.1 Drug Risk Benefit Score 30
7.5.2 Intensity of Competition 31
7.6 Sales Forecasts 32
7.6.1 Target Patient Pool of Afatinib 32
7.6.2 Dosing 32
7.6.3 Market Penetration 32
7.6.4 Annual Cost of Therapy 33
7.6.5 Sales Forecasts of Afatinib 33

8 Appendix 42
8.1 Market Definitions 42
8.2 Abbreviations 42
8.3 Research Methodology 42
8.3.1 Coverage 42
8.3.2 Secondary Research 43
8.3.3 Forecasting 43
8.3.4 Number of Patients Approved to Take the Drug 43
8.3.5 Net Penetration of Drug 43
8.3.6 Net Annual Dosing 44
8.3.7 Annual Cost of Therapy 44
8.4 Drug Sales Estimates Model 44
8.5 Contact Us 44
8.6 Disclaimer 44
8.7 Sources 45

List of Tables


Table 1: Breast Cancer, Incidences and Mortality, By Country, 2008-2030 5
Table 2: Five-Year Relative Survival Rates, 2005, By Stages 14
Table 3: Drug Risk Benefit Score 30
Table 4: Afatinib, Breast Cancer, Global, Sales Forecasts ($m), 2017–2020 33
Table 5: Afatinib, Breast Cancer, The US, Sales Forecasts ($m), 2017–2020 34
Table 6: Afatinib, Breast Cancer, The UK, Sales Forecasts ($m), 2017–2020 35
Table 7: Afatinib, Breast Cancer, France, Sales Forecasts ($m), 2017–2020 36
Table 8: Afatinib, Breast Cancer, Germany, Sales Forecasts ($m), 2017–2020 37
Table 9: Afatinib, Breast Cancer, Italy, Sales Forecasts ($m), 2017–2020 38
Table 10: Afatinib, Breast Cancer, Spain Sales Forecasts ($m), 2017–2020 39
Table 11: Afatinib, Breast Cancer, Japan, Sales Forecasts ($m), 2017–2020 40

List of Figures


Figure 1: Distribution by Incidence and Mortality, Most Commonly Diagnosed Cancers, Worldwide, 2010 6
Figure 2: Breast Cancer, Global, Market Size Forecasts ($bn), 20102020 9
Figure 3: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 10
Figure 4: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 11
Figure 5: Breast Cancer, Incidence, Worldwide, 2008-2030 11
Figure 6: All Cancers, Incidence, Worldwide, 2008-2030 12
Figure 7: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005 12
Figure 8: Breast Cancer, Mortality, Worldwide, 2008-2030 13
Figure 9: All Cancers, Mortality, Worldwide, 2008-2030 13
Figure 10: Broad Classification of Breast Cancer, By Type 15
Figure 11: Classification of Non-Invasive Breast Cancer, By CIS 15
Figure 12: Classification of Invasive Breast Cancer, By Stages 16
Figure 13: Classification of Invasive Breast Cancer, By Treatment 16
Figure 14: Current Molecular Biomarkers used in the Clinical Management of Breast Cancer 17
Figure 15: Breast Cancer Intrinsic Sub Types used for Deciding Treatment Options for MBC 18
Figure 16: Breast Cancer Types in Decreasing Order of their Aggressiveness 18
Figure 17: Treatment Options, DCIS Breast Cancer 19
Figure 18: Treatment Options, LCIS Breast Cancer 20
Figure 19: Classification of Stages I, II and IIIA 20
Figure 20: Treatment Options, Stages I, II and IIIA (HR Positive and Premenopausal Breast Cancer) 21
Figure 21: Treatment Options, Stages I, II and IIIA (HR Negative, Pre and Postmenopausal Breast Cancer) 21
Figure 22: Treatment Options, Stages I, II and IIIA (HR Positive Postmenopausal Breast Cancer) 22
Figure 23: Adjuvant Therapy for HR Positive, HER2 Negative Metastatic Breast Cancer 23
Figure 24: Hormonal Therapy in Adjuvant Setting in HR Positive, HER2 Negative MBC 23
Figure 25: Adjuvant and First Line Therapy for HR Negative, HER2 Negative Metastatic Breast Cancer 25
Figure 26: Treatment Options, HR Negative and HER2 Positive Metastatic Breast Cancer 26
Figure 27: Drug Model Diagram of Afatinib 32
Figure 28: Afatinib, Breast Cancer, Global, Sales Forecasts ($m), 20172020 33
Figure 29: Afatinib, Breast Cancer, The US, Sales Forecasts ($m), 20172020 34
Figure 30: Afatinib, Breast Cancer, The UK, Sales Forecasts ($m), 20172020 35
Figure 31: Afatinib, Breast Cancer, France, Sales Forecasts ($m), 20172020 36
Figure 32: Afatinib, Breast Cancer, Germany, Sales Forecasts ($m), 20172020 37
Figure 33: Afatinib, Breast Cancer, Italy, Sales Forecasts ($m), 20172020 38
Figure 34: Afatinib, Breast Cancer, Spain, Sales Forecasts ($m), 20172020 39
Figure 35: Afatinib, Breast Cancer, Japan, Sales Forecasts ($m), 20172020 40
Figure 36: Afatinib, Breast Cancer, Global, Sales Distribution by Country (%), 2020 41
Figure 37: Patients Approved for the Drug 43

Upcoming Reports:

Thin Wafer Market - Global Industry Size, Market Share, Trends, Analysis And Forecasts 2012 - 2018
By - Transparency Market Research
Consumer electronics market requires higher performing, lower cost device setups for various applications, thus resulting in the reduction of chip thickness from the traditional 500ì thickness to about 40 ìm.  Main applications which essentially require temporary bonding are Advanced Packaging applications (TSV, interposers and Fan out WLP), Power Devices (IG BTs), and RF Devices & LED s. To avoid difficulties during the production of such chips  various techniques and developments are being introduced in the traditional process, thus temporary...
Public/Private Cloud Storage Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
Cloud storage allows users to store data on a server which is remotely located. A service provider hosts the cloud service on a server which is safe from catastrophic failures such as fire, earthquake, and tsunamis. With daily additions in transactional information, it has become a challenge for companies to store such humongous amount of data. Cloud storage provides the solution via remote access through the internet. This market has grown exponentially in the last decade and is expected to take over traditional storage systems in the near future. This market is segmented...
Haptic And Touch Technology Market - Global Industry Analysis, Market Size, Share, Growth, And Forecast, 2012 - 2018
By - Transparency Market Research
Haptic technology is mechanical simulation used to create the sense of touch in computer and other electronic devices by using different forces, motion, and vibration. The haptic and touch screen technology market observed significant growth in the last few years with growing application in Smartphone devices, navigation devices, portable gaming devices, digital cameras, media players, tablet computers, and e-readers.  The global haptic and touch technology market is expected to grow at a CAGR of 11% from 2012 to 2018. North America represents the largest region for the...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.com
Select License type:

Share this report

Related News

Cable-free Charging Device Launched by the UPV
Aug 21, 2014  
A wireless energy transfer technology device has been developed by the researchers at the Universitat Politecnica de Valencia (UPV). The striking feature of this device is that one can charge electronic devices like laptops and mobile phones without using cables.  This patented system of the UPV makes use of resonators which have photonic crystals in which one is set on the...
Public Sector Employees Now Less Confident of Their Post-Retirement Security
Aug 21, 2014  
A new analysis reveals that employees in the public sector in the United States are more anxious today about their post-retirement safety than they were just two years ago.   The analysis says that only 18% of all full-time public sector employees that were a part of the survey said that they were ‘very confident’ about their post-retirement income security. This is a 3%...
Novartis to Handover Experimental TB drug to TB Alliance
Aug 21, 2014  
Novartis has signed a deal with the Global TB Alliance to handover its experimental tuberculosis medicine for further development and deployment, for no monitory gains it seems.  The deal is a clear indication how scrutiny over the company’s portfolio has been increased since Joerg Reinhardt took position as company’s new chairman. The new chairman is seen focusing more on...
Does Chewing Gum Lead to Academic Productivity?
Aug 20, 2014  
Could chewing gum actually lead to improved academic productivity? A study conducted recently has found that there may possibly be a link between the two, finally making some headway in a decade-old research. The study called ‘The Effects of Gum Chewing on Math Scores in Adolescents’ was led by Craig Johnston from Baylor College of Medicine in Houston, Texas, and was sponsored by...
German Arms Industrys Outlook Uncertain
Aug 20, 2014  
During a recent meeting between representatives of the German ammunition and arms industry and the German Ministry for Economic Affairs, the unionists discussed concerns about the declining approvals for German arms shipment contracts. Workers’ representatives had, earlier in July 2014, written to the German minister of economic affairs Sigmar Gabriel stating that these curbs on...